Compare DexCom, Inc. (DXCM) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs FTAI Aviation Ltd — how do they compare? DexCom, Inc. trades at $84.88 (market cap $31.86B), while FTAI Aviation Ltd trades at $168.78 (market cap $17.57B). The key difference: DexCom, Inc. is the larger of the two by market cap, and FTAI Aviation Ltd pays a 1.17% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and FTAI Aviation Ltd for 22 Days on average.
| DXCM | FTAI | |
|---|---|---|
Market Cap | $31.86B | $17.57B |
Volume | 3,607,070 | 1,905,014 |
Sector | Health | Industrials |
52-Week High | $92.34 | $310.04 |
52-Week Low | $54.84 | $152.80 |
Typical Hold Time | 62 Days | 22 Days |
Enterprise Value | $31.32B | $20.69B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
FTAI Aviation trades at $174.83, down 2.57% with a bearish technical signal despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51B in 2025 but missed Q2 2026 EPS estimates. Recent developments include a $500M share repurchase program and acquisition of 27 Boeing 737-700 aircraft, signaling strategic expansion in aerospace services.
FTAI presents a compelling growth story with 100% analyst buy consensus and $321.25 price target, but faces execution risks from negative operating cash flow and earnings misses. The transition to fee-based management and aerospace expansion offers upside potential, though high valuation multiples and cash flow concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
